Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why
03:10pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
03:12pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
04:01pm, Monday, 13'th Jun 2022 Zacks Investment Research
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
02:51pm, Friday, 10'th Jun 2022 Zacks Investment Research
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
02:48pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022
02:16pm, Thursday, 09'th Jun 2022 Benzinga
Upgrades
Keefe, Bruyette & Woods upgraded the previous rating for AGNC Investment Corp (NASDAQ:AGNC) from Market Perform to Outperform. In the first quarter, AGNC Investment showed an EPS of $0.72, co
Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease
02:14pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.
Praxis (PRAX) Tanks on Negative Data From Depression Study
03:30pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
03:23pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix
02:13pm, Monday, 06'th Jun 2022 Zacks Investment Research
The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
02:51pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.
Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug
02:49pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene edit
Caribou Charges Ahead on Study Results
03:07pm, Tuesday, 17'th May 2022
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the prese
Precision Bio: Another CAR-T Laggard With No Solid Prospects
01:36pm, Monday, 09'th May 2022
DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference.
